Clinical prognostic markers in stage IIIC melanoma.
Max F MaduJaap H H SchopmanDanique M S BergerWillem M C KlopKatarzyna JóźwiakMichel W J M WoutersJos A van der HageAlexander C J van AkkooiPublished in: Journal of surgical oncology (2017)
Although survival for patients with stage IIIC is poor in general, patients with both N3 disease and ECE constitute the group with the worst prognosis and should be considered for adjuvant therapy with ipilimumab or any other future effective adjuvant therapy (study).
Keyphrases